FDA Defends ‘Paradoxical’ Approval Of J&J’s TB Drug Sirturo In NEJM
This article was originally published in The Pink Sheet Daily
Executive Summary
Imbalance of deaths for bedaquiline patients despite efficacy on surrogate marker in Phase II study supporting accelerated approval is still unexplained with longer-term data. But with efficacy also still looking good, FDA defends approval for select population with high unmet need.
You may also be interested in...
J&J Bedaquline and the Evolving Role for Accelerated Approval: Confirming Safety, Not Efficacy?
Discussions during an advisory committee review Janssen’s TB drug bedaquiline showed some interesting thinking around accelerated approval and how much uncertainty can be acceptable—especially when it comes to safety.
Janssen’s Sirturo: TB Milestone Awaits After Advisory Committee Hurdle
Important safety questions remain for what could be the first new tuberculosis drug in 40 years, and there was a lack of efficacy in the key subgroup of black patients.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.